Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
y9r4CzmshzTYWjdp
Listen
